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Summary
A growing literature has highlighted important differences in transplant-related outcomes between 
men and women. In the United States there are fewer women than men on the liver transplant 
waitlist and women are two times less likely to receive a deceased or living-related liver transplant. 
Sex-based differences exist not only in waitlist but also in post-transplant outcomes, particularly in 
some specific liver diseases, such as hepatitis C. In the era of individualized medicine, recognition 
of these differences in the approach to pre and post-liver transplant care may impact short and 
long-term outcomes.
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Introduction
A growing literature has highlighted important differences in transplant-related outcomes 
between men and women. In the United States, there are fewer women than men on the liver 
transplant (LT) waitlist (38% vs. 62%) [1], and women are two times less likely to receive a 
deceased or living-related LT [2–4] (Fig. 1). While the MELD-based allocation system has 
decreased waitlist mortality by prioritizing the sickest patients awaiting LT [5], sex-based 
disparities in waitlist outcomes (Fig. 2) have not been overcome. Indications for transplant 
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(Figs. 3 and 4) and their respective disease course post-LT also vary by sex. This review 
focuses on the current knowledge of transplant-related outcomes in women with the goal of 
facilitating a more gender-specific management of transplant patients.
Age at transplant
Both men and women are most commonly transplanted between 50 and 64 years of age, 
though a somewhat higher percentage of women are transplanted in the older and younger 
age ranges. Among U.S. LT recipients in 2012, approximately 15% of women were 
transplanted at >65 years of age compared to 13% of men, and approximately 7% of women 
compared to 4% of men were transplanted between ages 18 and 34 years [1].
Transplant rates and waitlist mortality
Women remain disadvantaged in the post-MELD era with worse waitlist outcomes (Table 1) 
[6–9], with women 30% less likely than men to receive a transplant within 3 years of listing 
(OR 0.7; 95% CI 0.6–0.8; p <0.001) [9]. A recent US investigation of trends in LT rates 
found that in the pre-MELD era, women had a 9% lower adjusted transplant rate compared 
to men, which increased to a 14% difference (p <0.004) after implementation of MELD. The 
lower transplant rates among women compared to men appeared to predominate at higher 
MELD scores with 20% lower rates at MELD scores 20–29 and a 12% lower rate at MELD 
scores of 30–40 (p values <0.05). However, similar transplant rates were noted at MELD 
scores <15 [9]. Disparities in transplantation rates may translate into higher healthcare 
expenditures for waitlisted women, given the longer wait times and lower risk of non-liver-
related removal from the waitlist [9,10].
Recent data investigating the rate of waitlisting relative to those potentially eligible for 
transplant, have found that women may have greater access to the transplant waitlist, despite 
lower rates of transplantation than men [9,11]. These data also highlight an ongoing racial/
ethnic disparity for Hispanics, who have lower transplant rates compared to other racial/
ethnic groups in the post-MELD era, although sex-based disparities in transplant rates by 
race/ethnicity have not specifically been identified [11].
Women have also been shown to be at higher risk of death or becoming too sick for LT (OR 
1.3; 95% CI 1.1–1.5; p = 0.003) [7] (Fig. 2). This higher risk of waitlist mortality in women 
has been observed in most [12,13], but not all studies [9]. There are several hypotheses to 
explain sex differences in waitlist outcomes. A major focus has been on renal function 
measures. It has been proposed that less muscle mass in women results in lower creatinine 
levels for similar degrees of renal impairment than men, resulting in overall lower MELD 
scores [14,15]. Though creatinine levels do contribute to sex differences in waitlist 
outcomes, studies adjusting for estimated glomerular filtration rate (eGFR), and thereby 
accounting for gender differences in renal function, reveal persistent disparities in liver 
allocation and waitlist mortality [8,12,14]. In a study using iothalamate as a direct measure 
of GFR in wait-listed patients, women were more likely than men to have a pre-transplant 
GFR <60 ml/min (29% vs. 21%) and <30 ml/min (10% vs. 6%, respectively) [16]. A U.S.-
based study in the post-MELD era (n = 42,322) noted similar overall waitlist mortality, but 
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among patients with non-dialysis dependent End Stage Renal Disease (ESRD), women were 
more likely to die on the waitlist than men (26% vs. 20%; p = 0.001) [17]. Moreover, despite 
lower GFR levels, women were less likely to receive dialysis [18], and lower rates of dual 
liver-kidney transplant were reported in women compared to men with non-dialysis 
dependent ESRD (OR 0.5; p <0.001) [19].
Another potential reason for the higher waitlist mortality among women relates to physical 
stature. Deceased donors are more often male, thus with size matching, more likely to be 
allocated to men. In addition, preferential allocation of small or split livers to children may 
also limit the pool of available organs for women, contributing to longer waitlist times and 
higher risk waitlist dropout [6]. A UNOS-based study found that women had a 20% higher 
risk of death than men, after adjusting for age, region, blood type, disease etiology, race, and 
MELD but this difference largely disappeared with the addition of height to the model (HR 
1.04; 95% CI 0.98–1.1; p = 0.2) [13]. Another UNOS-based study found that although 
women were 25% less likely to undergo LT in a given month compared to men, this 
decreased to 17% with adjustment for renal function, and to 13% with further adjustment for 
liver volume [6]. These data suggest that like renal function, physical stature contributes to, 
but does not fully explain sex differences in waitlist outcomes.
Interestingly, while 35% of deceased-donor LT recipients are women, 44% of live donor 
transplants are in female recipients. The higher percentage of women receiving a live as 
compared to deceased donor transplant may be reflective of their smaller stature, and 
therefore better suitability for smaller, live donor grafts [1].
The implications of these findings are several-fold. First, continued efforts to find markers of 
renal function that are gender independent are essential. Second, nephrologists need to 
consider gender differences in their recommendations for renal replacement therapy and 
kidney transplant. Third, women should be encouraged to pursue living donation, and 
programs may need to consider splitting more organs to offset the longer wait times for 
women. Finally, continued evaluation of gender disparities as the MELD system evolves is 
critical for affecting outcomes in waitlisted women and informing future allocation policy.
Post-transplant outcomes
Patient and graft survival
Whether there are sex differences in post-transplant survival, remains controversial. A recent 
study from Germany (n = 266) found that female sex in the post-MELD era was a strong and 
independent risk factor for 90-day post LT mortality (OR 3.2; 95% CI 1.3–7.6; p = 0.009). 
Women had higher MELD scores at transplant than men in this study, and higher post LT 
mortality was only identified among individuals with pre-transplant MELD scores >20 (33% 
vs. 14%; p <0.05), and not among those with MELD scores <20 (10 vs. 4%; p >0.05) [20]. 
Recent data from the U.S. Scientific Registry of Transplant Recipients (SRTR) (n = 19,249) 
found higher donor risk indices in women than men (1.46 vs. 1.4; p <0.001), with a 24% 
higher odds among women receiving a low quality graft (OR 1.24; p <0.001). This is 
possibly driven by use of smaller grafts allocated to women, but with no difference in graft 
survival between women and men after adjustment for differences in graft quality [21].
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Donor gender has also been investigated as a factor influencing graft survival. Older studies 
report worse post-LT survival in gender mismatched transplants, with particularly high risk 
of graft loss noted in male recipients of female donors [22,23]. Recent data from Germany 
noting higher post-transplant mortality in women did not identify donor gender mismatch as 
a contributing factor [20]. Other studies indicate that donor quality, rather than donor gender 
or sex mismatch are more important in predicting graft survival. In composite, it remains 
unclear to what extent sex mismatch or receipt of a female donor, contribute to potential 
differential post-transplant outcomes.
Rejection
The immune profile of men and women are distinct, with women having been described as 
more “immunogenic” than men, with greater antibody production and higher rates of 
autoimmune conditions [24]. Sex differences in immune activity may also translate into 
different post-transplant immunosuppression needs. A recent multicenter trial investigating 
immunosuppression withdrawal after LT identified male sex as an independent predictor of 
successful weaning and subsequent development of immune tolerance (OR 4.7; p = 0.016) 
[25]. Interestingly, the opposite may hold true in the pediatric population, and maternal 
grafts in female recipients may also protect against rejection in children with biliary atresia 
[26,27]. In the hepatitis C population, female gender has been shown to predict early acute 
rejection (HR 1.8; 95% CI 1.2–2.7; p = 0.004) [28]. Although older studies suggest that 
female recipients of male livers may be predisposed to chronic rejection, in studies that 
include all liver conditions no definitive sex differences in risk of acute or chronic rejection 
have been demonstrated [29–31].
Renal dysfunction
Female sex has been shown to be an independent risk factor for post-transplant renal 
impairment [32–34] for similar reasons as described above. While earlier studies have been 
limited by use of indirect measures of renal function, a recent study using iothalamate as a 
direct measure of GFR also identified female sex as an independent predictor of Pstage 3 
CKD at 1 (OR 3.0; 95% CI 1.7–5.1; p <0.001) and 5 years post-transplant (OR 2.5; 95% CI 
1.3–4.7; p = 0.004). This finding appeared to be related to worse renal function in women 
compared to men in the pre-transplant setting [16].
Sarcopenia or physical condition
Recent data indicate that sarcopenia, or severe muscle depletion, is strongly associated with 
waitlist mortality, but with men at greater risk than women (OR 5.9; 2.4–14.6; p <0.001) 
[35]. Pre-transplant muscle mass is also emerging as an important predictor of post-
transplant outcomes. A study of 338 transplant candidates (223 men, 115 women) found that 
low muscle mass as determined by CT scan was strongly associated with post-transplant 
length of ICU stay, total length of hospital stay, and number of days requiring intubation, 
although this effect was modest in women and quite strong in men. In men, but not women, 
low muscle mass was also associated with worse post LT survival and hospital disposition 
[36,37]. The differential effect may be related to greater baseline muscle mass in men for 
whom a greater degree of cachexia and catabolism is reflected in the presence of sarcopenia, 
though further investigation is required.
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Quality of life
Data on sex differences in overall quality of life (QOL) after LT have been conflicting [38]. 
Older studies found no differences [39,40] whereas more recent data report lower QOL 
scores at 1 and 2 years in women compared to men [41], as well as worse psychosocial 
adjustment in women [42]. In contrast, a small study (n = 52) of patients transplanted for 
hepatitis C virus (HCV) found that women had significantly better mental health, emotional 
role functioning, as well as lower pain scores than men, whereas men felt they had better 
physical functionality after LT [43]. A larger post LT cohort (n = 386) including all liver 
diseases noted worse measures of physical distress and personal function in women, without 
apparent sex differences in psychological distress or general health perception [44]. Despite 
different methodologies for measuring specific QOL indictors, the overall findings indicate 
that sex differences in post LT QOL are apparent.
Cirrhosis is known to impair sexual function, an important QOL measure. Most men and 
women experience improved sexual function after LT [45], though one large study of 233 
transplanted women found no improvement in multiple measures of sexual satisfaction 
following transplant [46]. De novo sexual dysfunction following LT has been identified in 
33% of men and 26% of women (p value not reported) [47]. Persistent sexual dysfunction 
following transplant may relate to depression, and psychosocial interventions in the post LT 
setting may be underutilized [48]. Interestingly, a recent study found that marital happiness 
was not affected by LT in men, while women in the post LT setting experienced marked 
improvement in conjugal satisfaction, which correlated with sexual function in women (r = 
0.4; p = 0.02), but not in men (r = 0.1; p = 0.3) [45]. Chronic anovulation and symptoms of 
premature menopause are common problems in women with end-stage liver disease and 
most pre-menopausal women do have restoration of ovarian function and fertility after 
transplant [49]. Pregnancy outcomes in the post-LT setting have been well studied, though 
beyond the scope of the current review [50–53].
Non-hepatic complications following liver transplantation
With increased life expectancy, de novo tumors and cardiovascular disease are now leading 
causes of non-graft related death in long-term liver transplant survivors [54–56]. This high 
incidence of non-hepatic events is theoretically explained by the presence of pre-existing 
risk factors, as well as the introduction of additional risk factors associated with the organ 
transplant process, such as chronic exposure to immunosuppressive agents, life-style habits 
(weight gain, tobacco use), and/or the development of de novo metabolic disorders including 
post-transplant arterial hypertension, diabetes and/or dyslipidemia. With respect to 
cardiovascular risk factors and disease, no gender association has been found in most studies 
to date [54,57]. Interestingly, the fact that male gender is a known risk factor for malignancy 
in the general population but not in post-transplant studies suggests that women have closed 
the gap, and hence are at higher risk than women in the general population.
Overall, the risk of malignancy is 2 to 4 times higher in transplant recipients than in an age- 
and sex-matched population [58–62]. With the exception of a few studies where men appear 
to be more affected than women [62–65], there does not appear to be a clear gender-based 
difference in the incidence of de novo malignancy. Importantly, since the incidence rates of 
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breast cancer is not increased in organ transplant recipients, there is no evidence to suggest 
the need for breast cancer screening that would differ from the general population [54].
Post-transplant outcomes in specific liver diseases (Table 2)
Chronic hepatitis C
Chronic hepatitis C is an important cause of cirrhosis and hepatocellular carcinoma (HCC) 
globally. In the United States, Europe and Japan, HCV is the most common indication for 
LT. In recent years, the proportion of patients with HCC as the primary indication for LT has 
increased, likely reflecting prioritization of small HCC for LT as well as the increased 
prevalence of cirrhosis among HCV-infected persons [66,67]. Cirrhosis and its 
complications are less frequent in women than men [67] and this difference is likely due to 
the higher rates of spontaneous clearance among women [68], the protective effects of 
estrogens on fibrosis in premenopausal women [69], as well as lower frequency of cofactors 
associated with fibrosis in women, such as heavy alcohol use.
Recurrent disease is essentially universal among viremic patients after LT and the estimated 
median time to recurrent cirrhosis is 8–10 years [70] with rapid progressors advancing to 
cirrhosis within 3–5 years [71]. Approximately 10% develop severe early recurrence with 
cholestatic features within the first year post LT, which can rapidly progress to graft loss in 
the absence of antiviral therapy. Higher rates of severe HCV disease and reduced graft 
survival are associated with several recipient and donor factors, including African-American 
race, HIV co-infection, older donor age and IL28B polymorphisms. Women have more 
severe recurrent disease [72–74] with a 23% higher risk of advanced fibrosis than men after 
a median of 3 years after liver transplant [72]. Viral eradication prior to or after LT can 
prevent complications of HCV recurrence. Few studies have focused on sex differences in 
response to therapy, but the lower response rates to interferon-based therapy in women [75] 
are likely due to lower adherence to therapy and a higher rate of therapy discontinuation 
related to ribavirin-induced anemia. Sex differences in treatment response with direct acting 
antiviral therapies have not been studied, but the greater risk of ribavirin-associated toxicity 
may continue to limit therapy tolerability and efficacy in women (Table 3).
Non alcoholic fatty liver disease (NAFLD)
Non-alcoholic steatohepatitis (NASH) is the third most common indication for LT in the 
United States and is predicted to surpass HCV as the most common indication for LT in 10 
years’ time [76]. Most population-based studies note a higher prevalence of NAFLD in men, 
though clinically diagnosed and biopsy proven NASH appears to be higher in women [77–
79]. Hormonal factors may contribute to this difference, as a recent cross sectional study 
noted increased liver fibrosis in men with NASH compared to pre-menopausal women, but 
similar fibrosis scores as postmenopausal women [80]. Sex differences in NAFLD 
prevalence may also equalize after women reach menopause [81,82]. Patients receiving LT 
for NASH are equally distributed by sex [78], with no apparent sex differences in post LT 
patient or graft survival [83,84], or risk of recurrent NASH [85,86].
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Alcoholic liver disease (ALD)
There are clear sex differences in the hepatotoxic effects of alcohol, with higher risk of 
hepatic damage at lower doses of alcohol exposure in women (>10 g daily) compared to 
men (>20 g daily) [87]. This is in part related to lower levels of gastric alcohol 
dehydrogenase in women, which is involved in first pass alcohol metabolism [88]. Once 
diagnosed with ALD, women have more rapid acceleration of liver fibrosis than men, which 
may persist even after alcohol cessation [89]. Consistent with this finding, men on the 
waiting list for ALD tend to have longer median durations of alcohol abuse than women 
[90,91]. However, the overall prevalence of ALD remains higher in men, and a greater 
proportion of men undergo LT for ALD [90,92,93]. UNOS-based data from 2002 to 2012 
indicate that men account for 75% of patients transplanted for a primary diagnosis of ALD 
[78].
Most studies have not identified sex differences in post LT graft or patient survival for ALD 
[91,93], though one older study noted a higher percentage of women than men surviving at 5 
years (78% vs. 58%, respectively, no p-value provided) [94]. A French study identified de 
novo malignancies as an independent risk factor for lower post LT survival in ALD and 
though sex was not predictive on multivariate analysis, male sex was strongly associated 
with the risk of de novo malignancy [93].
Data on sex differences in recidivism rates are conflicting. A Scandinavian study (n = 103) 
found no association between sex and recidivism [95], while a Canadian study (n = 80) 
noted higher recidivism in women, accounting for 5/8 patients that resumed problem 
drinking. Interestingly, 4/5 of these women had a pre-transplant diagnosis of depression, 
which may contribute to the higher observed recidivism in women [96]. A U.S.-based study 
has since reported depression to be a strong predictor of post LT recidivism, though sex was 
not specifically investigated in this model [90].
Autoimmune hepatitis (AIH)
Like most autoimmune conditions, AIH is more prevalent in women than men, with a sex 
ratio of 3.6:1 [97]. Women comprise the majority of patients that receive LT for AIH, though 
a recent study (n = 1318) identified male sex as an independent predictor of mortality or 
need for LT (HR 1.5 compared to women, 95% CI 1.2–2.2; no p-value reported). In this 
study, cirrhotic women with AIH also had a lower HCC incidence rate per 1000 person-
years compared to men (0.6 vs. 5.5) [98]. A smaller study (n = 138) noted a higher 
unadjusted risk of cirrhosis at the time of AIH diagnosis in men than women (OR 2.8; 95% 
CI 1.2–6.2; p = 0.01) though risk of mortality or need for LT was not different [99]. 
Interestingly, there are no apparent recipient sex differences in risk of de novo autoimmune 
hepatitis (HR 0.8; 95% CI 0.3–2.3; p = 0.7), although the risk of de novo AIH appears to be 
higher in recipients of female donors regardless of recipient sex (HR 3.0; 95% CI 1.1–8.3; p 
= 0.03) [100]. To date, sex differences in risk of post LT survival, recurrent AIH, or risk of 
rejection have not been identified [101–103].
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Primary biliary cirrhosis (PBC)
Like AIH, PBC is more common in women accounting for ~90% of PBC cases [104]. 
Women with PBC tend to be younger at the time of diagnosis, with worse fatigue and 
pruritus than men, and higher risk for concomitant autoimmune conditions. Interestingly, 
recent data note similar fatigue and cognitive symptoms in women after LT compared to sex 
matched non-transplant controls (p values >0.05), whereas transplanted men compared to 
non-transplant controls had worse fatigue (p <0.05) and cognitive symptoms (p <0.005) 
[105]. Pre-LT serologic profiles are similar in men and women, though men have more 
progressive disease and overall worse outcomes [101,106,107]. A recent large study (n = 
2,353) found that men were less responsive to ursodeoxycholic acid, based on ALT, total 
bilirubin and alkaline phosphatase levels (OR 0.9; 95% CI 0.83–0.97; p = 0.007) [108]. 
Similar to most chronic liver diseases, the incidence of HCC in PBC patients with cirrhosis 
is lower in women than men, with a recent study noting a 10-year HCC incidence of 2.0% in 
women vs. 6.5% in men (p <0.001) [109–112]. Though HCC in women is predominantly 
seen in cirrhosis, men with PBC have been diagnosed with HCC at all stages of fibrosis 
[112]. Data are limited on post LT sex differences in patient or graft survival, though 
recurrent PBC or risk of rejection appears to be similar between sexes [101,113].
Primary sclerosing cholangitis (PSC)
Unlike PBC and AIH, PSC is less common in women, with more than 60% of cases 
diagnosed in men, and no major differences in clinical presentation [114]. While most 
studies have not identified a difference in overall survival [115,116] a regional study from 
Sweden (142 men and 57 women) identified female sex as a strong and independent risk 
factor for death or need for LT (RR 2.0; 95% CI 1.1–3.7; p = 0.02) [117]. The reasons for 
the discrepancy in survival outcomes between this and other studies are not clear, but may be 
related to delayed diagnosis in women as this condition is more typically associated with 
men. Sex differences in genetic factors contributing to PSC-related outcomes have been 
identified. The rs738409 variant (I148M) of the PNPLA3 gene was recently shown to 
predict survival in patients with PSC with concurrent dominant strictures, although this 
effect was restricted to men (mean survival 11.9 years in I148M carriers vs. 18.8 years in 
wildtype; p <0.001), and did not predict survival in women (p = 0.65) [118].
Data reporting sex differences in post LT outcomes in PSC are limited. A single center study 
(n = 83) noted a smaller proportion of women than men with post LT biliary complications, 
revisions of the transplanted liver, and/or death (32% vs. 65%, p = 0.02) [119]. To date, no 
studies have demonstrated differences in risk for recurrent PSC on adjusted analyses [120–
122] or differences in risk of rejection [101]. A study of 61 women and 119 men following 
LT for PSC identified a higher incidence of de novo colorectal cancer in women (SIR 17.6; 
95% CI 3.6–51.4) [123], though other studies have not identified sex differences in risk of 
post LT malignancy for patients with PSC [124,125].
Hepatocellular carcinoma
The risk ratio of HCC in cirrhotic women vs. men ranges from 1:2 to 1:4 [126]. Sex 
differences in HCC risk also extend to chronic non-cirrhotic HBV infection for which the 
AASLD recommends initiation of HCC screening in non-cirrhotic Asian women at age 50 
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years compared to 40 years in Asian men [127]. A large Italian study (482 women and 1352 
men) investigating all etiologies of liver disease found that women were older at HCC 
diagnosis, had higher alpha-fetoprotein levels, and were more likely to have smaller, 
unifocal and well-differentiated HCCs, with lower likelihood of presenting with metastases. 
Though overall survival was better in women than men, there were no differences in 
likelihood of undergoing curative treatment such as transplant or resection. In this study 
survival differences disappeared when subgroup analyses were performed among individuals 
diagnosed with HCC by surveillance imaging opposed to symptomatic presentation, 
suggesting that sex differences in presentation and outcomes may have been related to 
differential receipt of HCC surveillance, rather than sex differences in tumor biology [128]. 
In a recent study from the U.S. Surveillance, Epidemiology, and End Results database, 
women with HCC were found to have a significantly greater median overall survival 
compared with men, independent of age, race, disease stage, or treatment (11 vs. 10 months; 
HR 0.93; 95% CI, 0.91–0.96, p <0.001). Interestingly, greater survival in women was noted 
among those who received surgical resection (HR 0.87; 95% CI 0.78–0.96; p = 0.01) but not 
among those receiving liver-directed therapy or LT [129]. In another U.S.-based study 
women were more likely to receive curative resection than men. Though adjusted analyses 
revealed lower risk of decompensation in women than men (OR 0.79; p <0.001), these 
authors found that among those with compensated cirrhosis and HCC, women were still 
more likely to be offered curative therapy. No differences in rates of LT were noted for 
patients with HCC, similar to previously reported UNOS data [7,130]. In the latter study, 
tumor characteristics were not available, therefore higher rates of resection in women may 
be related to lower tumor burden, as demonstrated in the Italian study [128]. Recipient sex 
does not appear to predict risk of recurrent HCC post LT [131–133].
Acute liver failure
A high female predominance is observed in acute liver failure of most etiologies, not only 
those associated with autoimmunity, though the reason for this association is not clear. In 
particular, acute liver failure due to Wilson disease occurs predominantly in young females 
with a female to male ratio of 4:1. Furthermore, approximately 10% of patients with 
hepatotoxicity due to medical/recreational drugs or herbal products may progress to 
fulminant hepatic failure, potentially requiring LT. While sex does not seem to increase the 
overall risk of drug-induced liver injury, the severity may differ by sex, with a predominance 
of severe cases observed in women [134–136].
Conclusions
LT remains the optimal treatment for patients with end-stage liver disease, though sex 
differences in access to transplant persist. In this review, we highlight sex-based disparities 
in transplant outcomes, as well as sex differences in transplant indications, some of which 
are quite marked and others more subtle. Despite clear differences in waitlist outcomes, the 
reasons for this particular disparity remain only partially understood. Further data are clearly 
needed to narrow the gender gap in transplant-related events, and to facilitate interventions 
that may optimize the management of women in both the pre- and post-transplant period.
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Abbreviations
MELD model for end-stage liver disease
QOL quality of life
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IFN interferon
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Key Points
• Transplant indications, waitlist outcomes, and post-transplant course vary by 
sex
• Waitlist outcomes (liver allocation and waitlist mortality) remain worse in 
women in the post model for end-stage liver disease (MELD) era, particularly 
at high MELD scores. Inadequate renal function measures that underestimate 
renal impairment in women, as well as differences in physical stature 
contribute to, but do not fully explain sex differences in waitlist outcomes
• Despite different methodologies for measuring specific quality of life (QOL) 
indicators, the overall findings indicate that women have lower QOL scores 
post-liver transplantation (LT) compared to men
• While overall post-transplant graft and patient survival do not seem to differ 
by sex, in some specific liver diseases, particularly in hepatitis C, sex 
differences are evident (more severe recurrent disease and lower response 
rates to interferon-ribavirin based therapies in women)
• Data on sex differences in alcohol recidivism rates are conflicting
• Recipient sex does not appear to predict risk of recurrent hepatocellular 
carcinoma (HCC) post-LT
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Fig. 1. Post-MELD era waitlist and transplant numbers by sex
(A) Post-MELD era waitlist by sex. Number of women and men in the U.S. listed for liver 
transplant based on data from the Scientific Registry of Transplant Recipients (SRTR) in the 
post-MELD era. (B) Post-MELD era transplant numbers by sex. Number of women and men 
receiving live and deceased donor liver transplants in the U.S. based on SRTR data in the 
post-MELD era.
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Fig. 2. Post-MELD era waitlist mortality by sex
Number of deaths among women and men in the U.S. based on SRTR data in the post-
MELD era. Those delisted as too sick for transplant are not included.
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Fig. 3. Indications for liver transplantation in 2013 in the US by sex
(A) Indications for liver transplants in 2013 among U.S. women based on UNOS data. (B) 
Indications for liver transplants in 2013 among U.S. men based on UNOS data. ALD, 
alcohol liver disease; PBC, primary biliary cirrhosis; HCV, hepatitis C virus; HCC, 
hepatocellular carcinoma; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; 
HBV, hepatitis B virus; NAFLD, non-alcoholic fatty liver disease.
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Fig. 4. Indications for liver transplantation in 2012 in Europe by sex
(A) Indications for liver transplants in 2012 among European women based on ELTR data. 
(B) Indications for liver transplants in 2012 among European men based on ELTR data (data 
kindly provided by V. Karam).
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Table 1
Key sex differences in waitlist outcomes in the post-MELD era.
Waitlist times and transplant rates • Women spend longer on waitlist [2-4,7-9]
• Transplant rates are higher in men [7-9]
Waitlist mortality • Many studies note higher mortality [7,12,13] in women, but not all [9]
Size • Patient height/liver volume contribute to sex disparity in transplant rates and waitlist mortality [6,13]
Renal function • Waitlisted women have lower creatinine for similar degree of renal failure [8,12,14-16]
• Creatinine and MELD scores inadequately reflect renal dysfunction in women
Sarcopenia • Sarcopenia is strongly associated with waitlist mortality
• Women may have lower risk of sarcopenia [35]
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Table 2
Sex differences in overall post LT outcomes.
Outcome Sex difference Comment
Patient/graft survival Controversial German study identified higher 90-day mortality in women [20]. U.S. study did not identify 
sex difference [21]
Rejection risk No No overall sex difference in acute or chronic rejection [29-31] though higher risk of early 
acute rejection in women with HCV [28]. Women less likely to wean from IMS and develop 
immune tolerance [25]
Quality of life Yes Considerable variability in the definition of specific QOL indicators though differences in 
sexual function, emotional and physical well-being are apparent
Renal function Yes Women at higher risk of CKD post LT [16,32-34]
Post LT recovery and 
sarcopenia
Yes In men, but less so women, sarcopenia is associated with worse post LT survival and post 
operative recovery [36-37]
J Hepatol. Author manuscript; available in PMC 2018 May 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sarkar et al. Page 25
Table 3
Sex differences in liver transplant by disease.
Liver disease Epidemiology Risk of cirrhosis/need for LT Post-LT outcome
HCV • Less common 
in women [67]
• Lower need for LT in women: 
related to higher spontaneous 
clearance, lower risk of fibrosis, 
and less concurrent alcohol use 
[66-68]
• Fibrosis progression may be more 
rapid in post- than pre-
menopausal women [69]
• Women at higher risk of 
graft loss [72-74]
• Possible lower risk of 
interferon response post 
LT [75]
• No apparent difference in 
response to new direct 
acting antivirals
• Women at higher risk of 
early acute rejection [28]
NASH • NAFLD more 
common in 
men
• Biopsy proven 
NASH higher 
in women 
[77-79]
• Similar rates of fibrosis in men 
and pre-menopausal women 
[81-82]. Fibrosis progression may 
be more rapid in post-than pre-
menopausal women [80]
• Similar transplant rates [78]
Similar rates of recurrent disease, 
patient, and graft survival [83-86]
ALD • Less common 
in women 
[90,92,93]
• Women at higher risk of cirrhosis 
with lower doses of alcohol 
exposure [87]
• Men account for 75% of 
transplants for ALD [78]
• Similar patient and graft 
survival [91-94]
• Recidivism controversial: 
may be higher in women 
[95-96]
AIH • More common 
in women, sex 
ratio 3.6:1 [97]
• Controversial: male sex 
predictive of death or need for LT 
[98-99]
• Women with AIH at lower risk 
for HCC [98]
• Similar post LT survival, 
recurrent AIH, and risk of 
rejection [101-103]
PBC • 90% diagnosed 
in women [104]
• Women more responsive to 
ursodiol [108]
• Women have less progressive 
disease [101,106,107]
• Women with PBC at lower risk 
for HCC [109-112]
• Similar risk of recurrent 
PBC and rejection 
[101,113]
• Limited data on post LT 
survival differences
PSC • 60% diagnosed 
in men [114]
• Controversial: Most studies show 
no difference in transplant-free 
survival [115,116]
• One study found female sex 
predictive of death or need for 
liver transplant [117]
• Similar risk of recurrent 
PSC [120-122] and 
rejection [101]
• Limited data on post LT 
survival differences
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